**PFIZER-BIONTECH COVID-19 VACCINATION SCHEDULE AND DOSING**

**FOR NON-IMMUNOCOMPROMISED POPULATIONS**

---

**Pfizer-BioNTech**  
**Ages 6 months–4 years**
- **dose/injection volume**: (dilute before use)
- **Primary Dose**: Maroon Cap
  - **DOSE 1**: PRIMARY, 3 μg/0.2 mL, In 3-8 weeks
  - **DOSE 2**: PRIMARY, 3 μg/0.2 mL
  - **DOSE 3**: PRIMARY, 3 μg/0.2 mL, In at least 8 weeks

**Pfizer-BioNTech**  
**Ages 5 years–11 years**
- **dose/injection volume**: (dilute before use)
- **Primary/Booster Dose**: Orange Cap
  - **DOSE 1**: PRIMARY, 10 μg/0.2 mL, In 3-8 weeks
  - **DOSE 2**: PRIMARY, 10 μg/0.2 mL
  - **DOSE 3**: BOOSTER, 10 μg/0.2 mL, In at least 5 months

**Pfizer-BioNTech**  
**Ages 12 years and older**
- **dose/injection volume**: (Do NOT dilute before use)
- **Primary Dose**: Gray Cap
  - **DOSE 1**: PRIMARY, 30 μg/0.3 mL, In 3-8 weeks
  - **DOSE 2**: PRIMARY, 30 μg/0.3 mL
  - **DOSE 3**: BIVALENT, 30 μg/0.3 mL, In at least 2 months

---

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years. Source: CDC.